Beyond Surgical Treatment in Adenoid Cystic Carcinoma of the Head and Neck: A Literature Review

References

• Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck-An update. Oral Oncol. 2015;51:652–661. doi:10.1016/j.oraloncology.2015.04.005
   PubMed Web of Science ®Google Scholar
• Li N, Xu L, Zhao H, El-Naggar AK, Sturgis EM. A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry. Cancer. 2012;118:3945–3953. doi:10.1002/cncr.26740
   PubMed Web of Science ®Google Scholar
• Moskaluk CA. Adenoid cystic carcinoma: clinical and molecular features. Head Neck Pathol. 2013;7:17–22. doi:10.1007/s12105-013-0426-3
   PubMedGoogle Scholar
• Gondivkar SM, Gadbail AR, Chole R, Parikh RV. Adenoid cystic carcinoma: a rare clinical entity and literature review. Oral Oncol. 2011;47:231–236. doi:10.1016/j.oraloncology.2011.01.009
   PubMed Web of Science ®Google Scholar
• Bradley PJ. Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngol Head Neck Surg. 2004;12:127–132. doi:10.1097/00020840-200404000-00013
   PubMedGoogle Scholar
• Dantas AN, de Morais EF, de Macedo RA. Clinicopathological characteristics and perineural invasion in adenoid cystic carcinoma: a systematic review. Braz J Otorhinolaryngol. 2015;81:329–335. doi:10.1016/j.bjorl.2014.07.016
   PubMed Web of Science ®Google Scholar
• Simpson RHW, Skálová A, Di Palma S, Leivo I. Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch. 2014;465:371–384. doi:10.1007/s00428-014-1639-x
   PubMed Web of Science ®Google Scholar
• Jaso J, Malhotra R. Adenoid cystic carcinoma. Arch Pathol Lab Med. 2011;135:511–515. doi:10.1043/2009-0527-RS.1
   PubMed Web of Science ®Google Scholar
• Hellquist H, Skalova A. Histopathology of the Salivary Glands, Chapter 8. Adenoid Cystic Carcinoma. Heidelberg: Springer-Verlag; 2014.
   Google Scholar
• Szanto PA, Luna MA, Tortoledo ME, White RA. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer. 1984;54:1062–1069. doi:10.1002/1097-0142(19840915)54:6<1062::AID-CNCR2820540622>3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Badoual C, Baglin A-C, Wassef M, et al. Pathologists and the French network of expertise on rare cancers ENT: the REFCORpath. Ann Pathol. 2014;34:64–69. doi:10.1016/j.annpat.2014.01.006
   PubMed Web of Science ®Google Scholar
• Van Weert S, Van der Waal I, Witte BI, Leemans CR, Bloemena E. Histopathological grading of adenoid cystic carcinoma of the head and neck: analysis of currently used grading systems and proposal for a simplified grading scheme. Oral Oncol. 2015;51:71–76. doi:10.1016/j.oraloncology.2014.10.007
   PubMed Web of Science ®Google Scholar
• Edwards PC, Bhuiya T, Kelsch RD. Assessment of p63 expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and basal cell and canalicular adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:613–619. doi:10.1016/S1079210403005742
   PubMed Web of Science ®Google Scholar
• Tasoulas J, Tsourouflis G, Klijanienko J, Theocharis S. Polymorphous adenocarcinoma: an overview of immunohistochemical features and insights on molecular pathology. Histol Histopathol. 2019;34(7):731–744. doi:10.14670/HH-18-089
   PubMed Web of Science ®Google Scholar
• Frierson HF, El-Naggar AK, Welsh JB, et al. Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol. 2002;161:1315–1323. doi:10.1016/S0002-9440(10)64408-2
   PubMed Web of Science ®Google Scholar
• Daa T, Kashima K, Kaku N, Suzuki M, Yokoyama S. Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma. Mod Pathol. 2004;17:1475–1482. doi:10.1038/modpathol.3800209
   PubMed Web of Science ®Google Scholar
• Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:586–593. doi:10.1067/moe.2003.31
   PubMed Web of Science ®Google Scholar
• Ito FA, Ito K, Coletta RD, Graner E, de Almeida OP, Lopes MA. Salivary gland tumors: immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67. Anal Quant Cytol Histol. 2009;31:280–287.
   PubMedGoogle Scholar
• Gibbons MD, Manne U, Carroll WR, Peters GE, Weiss HL, Grizzle WE. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope. 2001;111(8):1373–1378. doi:10.1097/00005537-200108000-00011
   PubMed Web of Science ®Google Scholar
• Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45:791–798. doi:10.1038/ng.2643
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Davies HR, Mitani Y, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013;123:2965–2968. doi:10.1172/JCI67201
   PubMed Web of Science ®Google Scholar
• Bradley PJ. Adenoid cystic carcinoma evaluation and management: progress with optimism Curr Opin Otolaryngol Head Neck Surg. 2017;25:147–153. doi:10.1097/MOO.0000000000000347
   PubMed Web of Science ®Google Scholar
• Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA. 2009;106:18740–18744. doi:10.1073/pnas.0909114106
   PubMed Web of Science ®Google Scholar
• Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008;8:523–534. doi:10.1038/nrc2439
   PubMed Web of Science ®Google Scholar
• Drabsch Y, Robert RG, Gonda TJ. MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res. 2010;12:R55. doi:10.1186/bcr2614
   PubMed Web of Science ®Google Scholar
• Persson M, Andrén Y, Moskaluk CA, et al. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer. 2012;51:805–817. doi:10.1002/gcc.21965
   PubMed Web of Science ®Google Scholar
• Seethala RR, Stenman G. Update from the 4th Edition of the World Health Organization classification of head and neck tumours: tumors of the salivary gland. Head Neck Pathol. 2017;11:55–67. doi:10.1007/s12105-017-0795-0
   PubMed Web of Science ®Google Scholar
• Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol. 2013;7:12–19. doi:10.1007/s12105-013-0462-z
   PubMedGoogle Scholar
• Andersson MK, Afshari MK, Andrén Y, Wick MJ, Stenman G. Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGF1R/AKT signaling. J Natl Cancer Inst. 2017;109. doi: 10.1093/jnci/djx017.
   PubMedGoogle Scholar
• Subramaniam T, Lennon P, O’Neill JP. Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck. Ir J Med Sci. 2015;184:583–590. doi:10.1007/s11845-015-1298-1
   PubMed Web of Science ®Google Scholar
• Bell D, Hanna EY. Head and neck adenoid cystic carcinoma: what is new in biological markers and treatment? Curr Opin Otolaryngol Head Neck Surg. 2013;21:124–129. doi:10.1097/MOO.0b013e32835c05fd
   PubMed Web of Science ®Google Scholar
• Xie M, Wei S, Wu X, Li X, You Y, He C. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival. Lung Cancer. 2018;121:41–47. doi:10.1016/j.lungcan.2018.04.020
   PubMed Web of Science ®Google Scholar
• Ferrarotto R, Mitani Y, Diao L, et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to notch1 inhibitors. J Clin Oncol. 2017;35:352–360. doi:10.1200/JCO.2016.67.5264
   PubMed Web of Science ®Google Scholar
• Geiger JL, Ismaila N, Beadle B, et al. Management of salivary gland malignancy: ASCO guideline. J Clin Oncol. 2021;39:1909–1941. doi:10.1200/JCO.21.00449
   PubMed Web of Science ®Google Scholar
• Lonneux M, Hamoir M, Reychler H, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010;28:1190–1195. doi:10.1200/JCO.2009.24.6298
   PubMed Web of Science ®Google Scholar
• Tomura N, Mizuno Y, Saginoya T. PET/CT findings for tumors in the base of the skull: comparison of 18 F-FDG with 11 C-methionine. Acta Radiol. 2016;57:325–332. doi:10.1177/0284185115575342
   PubMed Web of Science ®Google Scholar
• Jung JH, Lee SW, Son SH, et al. Clinical impact of18F-FDG positron emission tomography/CT on adenoid cystic carcinoma of the head and neck. Head Neck. 2017;39:447–455. doi:10.1002/hed.24605
   PubMed Web of Science ®Google Scholar
• Kim D, Kim W, Lee J, et al. Pretreatment maximum standardized uptake value of (18) F-fluorodeoxyglucose positron emission tomography as a predictor of distant metastasis in adenoid cystic carcinoma of the head and neck. Head Neck. 2016;38:755–761. doi:10.1002/hed.23953
   PubMed Web of Science ®Google Scholar
• Freling N, Crippa F, Maroldi R. Staging and follow-up of high-grade malignant salivary gland tumours: the role of traditional versus functional imaging approaches - A review. Oral Oncol. 2016;60:157–166. doi:10.1016/j.oraloncology.2016.04.016
   PubMed Web of Science ®Google Scholar
• Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18–28. doi:10.1016/1078-1439(95)00002-Y
   PubMedGoogle Scholar
• Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–1705. doi:10.2967/jnumed.115.161299
   PubMed Web of Science ®Google Scholar
• Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-A preliminary analysis. Eur J Nucl Med Mol Imaging. 2017;44:1614–1621. doi:10.1007/s00259-017-3737-x
   PubMed Web of Science ®Google Scholar
• Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. John Wiley & Sons; 2017.
   Google Scholar
• Simpson RH. Classification of tumours of the salivary glands. Histopathology. 1994;24:187–191. doi:10.1111/j.1365-2559.1994.tb01303.x
   PubMed Web of Science ®Google Scholar
• Meyers M, Granger B, Herman P, et al. Head and neck adenoid cystic carcinoma: a prospective multicenter REFCOR study of 95 cases. Eur Ann Otorhinolaryngol Head Neck Dis. 2016;133:13–17. doi:10.1016/j.anorl.2015.09.009
   PubMed Web of Science ®Google Scholar
• Amit M, Na’ara S, Trejo-Leider L, et al. Defining the surgical margins of adenoid cystic carcinoma and their impact on outcome: an international collaborative study. Head Neck. 2017;39(5):1008–1014. doi:10.1002/hed.24740
   PubMed Web of Science ®Google Scholar
• Atallah S, Moya-Plana A, Malard O, et al. Should a neck dissection be performed on patients with cN0 adenoid cystic carcinoma? A REFCOR propensity score matching study. Eur J Cancer. 2020;130:250–258. doi:10.1016/j.ejca.2019.12.026
   PubMed Web of Science ®Google Scholar
• Girelli L, Locati L, Galeone C, et al. Lung metastasectomy in adenoid cystic cancer: is it worth it? Oral Oncol. 2017;65:114–118. doi:10.1016/j.oraloncology.2016.10.018
   PubMed Web of Science ®Google Scholar
• Dubergé T, Bénézery K, Resbeut M, et al. Adenoid cystic carcinoma of the head and neck: a retrospective series of 169 cases. Cancer Radiother. 2012;16:247–256. doi:10.1016/j.canrad.2012.02.003
   PubMed Web of Science ®Google Scholar
• Balamucki CJ, Amdur RJ, Werning JW, et al. Adenoid cystic carcinoma of the head and neck. Am J Otolaryngol. 2012;33:510–518. doi:10.1016/j.amjoto.2011.11.006
   PubMed Web of Science ®Google Scholar
• Chen AM, Bucci MK, Weinberg V, et al. Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys. 2006;66:152–159. doi:10.1016/j.ijrobp.2006.04.014
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Hinerman RW, Villaret DB. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck. 2004;26(2):154–162. doi:10.1002/hed.10380
   PubMed Web of Science ®Google Scholar
• Hernán MA, Clayton D, Keiding N. The Simpson’s paradox unraveled. Int J Epidemiol. 2011;40:780–785. doi:10.1093/ije/dyr041
   PubMed Web of Science ®Google Scholar
• Iseli TA, Karnell LH, Graham SM, et al. Role of radiotherapy in adenoid cystic carcinoma of the head and neck. J Laryngol Otol. 2009;123:1137–1144. doi:10.1017/S0022215109990338
   PubMed Web of Science ®Google Scholar
• Fokas E, Kraft G, An H, Engenhart-Cabillic R. Ion beam radiobiology and cancer: time to update ourselves. Biochim Biophys Acta. 2009;1796:216–229. doi:10.1016/j.bbcan.2009.07.005
   PubMed Web of Science ®Google Scholar
• Huber PE, Debus J, Latz D, et al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol. 2001;59:161–167. doi:10.1016/S0167-8140(00)00273-5
   PubMed Web of Science ®Google Scholar
• Laramore GE, Krall JM, Griffin TW, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys. 1993;27:235–240. doi:10.1016/0360-3016(93)90233-l
   PubMed Web of Science ®Google Scholar
• Takagi M, Demizu Y, Hashimoto N, et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck. Radiother Oncol. 2014;113:364–370. doi:10.1016/j.radonc.2014.11.031
   PubMed Web of Science ®Google Scholar
• Mizoe JE, Hasegawa A, Jingu K, et al. Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol. 2012;103:32–37. doi:10.1016/j.radonc.2011.12.013
   PubMed Web of Science ®Google Scholar
• Jensen AD, Nikoghosyan AV, Lossner K, et al. COSMIC: a regimen of IMRT plus dose escalated rasted scanned carbon ion boost for malignant salivary gland tumors: results of the prospective Phase II Trial. Int J Radiat Oncol Biol Phys. 2015;93(1):37–46. doi:10.1016/j.ijrobp.2015.05.013
   PubMed Web of Science ®Google Scholar
• Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12:815–824. doi:10.1016/S1470-2045(10)70245-X
   PubMed Web of Science ®Google Scholar
• Licitra L, Marchini S, Spinazzè S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer. 1991;68:1874–1877. doi:10.1002/1097-0142(19911101)68:9<1874::aid-cncr2820680904>3.0.co;2-s
   PubMed Web of Science ®Google Scholar
• Mattox DE, Von Hoff DD, Balcerzak SP. Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck. Invest New Drugs. 1990;8:105–107. doi:10.1007/BF00216934
   PubMed Web of Science ®Google Scholar
• Verweij J, de Mulder PH, de Graeff A, et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1996;7:867–869. doi:10.1093/oxfordjournals.annonc.a010770
   PubMed Web of Science ®Google Scholar
• Airoldi M, Bumma C, Bertetto O, Gabriele P, Succo G, Pedani F. Vinorelbine treatment of recurrent salivary gland carcinomas. Bull Cancer. 1998;85:892–894.
   PubMed Web of Science ®Google Scholar
• Cherifi F, Rambeau A, Johnson A, et al. Systemic treatments of metastatic or locally recurrent adenoid cystic carcinoma of the head and neck, a systematic review. Bull Cancer. 2019;106:923–938. doi:10.1016/j.bulcan.2019.05.003
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1993;4:785–788. doi:10.1093/oxfordjournals.annonc.a058665
   PubMed Web of Science ®Google Scholar
• Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006;28:197–204. doi:10.1002/hed.20327
   PubMed Web of Science ®Google Scholar
• van Herpen CML, Locati LD, Buter J, et al. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer (Oxf Engl. 1990;2008(44):2542–2545.
   Google Scholar
• Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001;91:541–547. doi:10.1002/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Rodriguez CP, Martins RG, Baik C, et al. Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. Head Neck. 2018;40:584–589. doi:10.1002/hed.25020
   PubMed Web of Science ®Google Scholar
• Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res. 2000;20:3781–3783.
   PubMed Web of Science ®Google Scholar
• Hill ME, Constenla DO, A’Hern RP, et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol. 1997;33:275–278. doi:10.1016/S0964-1955(97)00026-2
   PubMed Web of Science ®Google Scholar
• Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996;7:640–642. doi:10.1093/oxfordjournals.annonc.a010684
   PubMed Web of Science ®Google Scholar
• Gedlicka C, Schüll B, Formanek M, et al. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Anticancer Drugs. 2002;13:491–495. doi:10.1097/00001813-200206000-00007
   PubMed Web of Science ®Google Scholar
• Bilen MA, Fu S, Falchook GS, et al. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015;75:869–874. doi:10.1007/s00280-015-2695-x
   PubMed Web of Science ®Google Scholar
• Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck. 2011;33:905–911. doi:10.1002/hed.21458
   PubMed Web of Science ®Google Scholar
• Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007;43:33–36. doi:10.1016/j.oraloncology.2005.12.026
   PubMed Web of Science ®Google Scholar
• Jakob JA, Kies MS, Glisson BS, et al. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015;37:644–649. doi:10.1002/hed.23647
   PubMed Web of Science ®Google Scholar
• Locati LD, Perrone F, Cortelazzi B, et al. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact. Eur J Cancer. 2016;69:158–165. doi:10.1016/j.ejca.2016.09.022
   PubMed Web of Science ®Google Scholar
• Ho AL, Dunn L, Sherman EJ, et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 2016;27:1902–1908. doi:10.1093/annonc/mdw287
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011;117:3374–3382. doi:10.1002/cncr.25852
   PubMed Web of Science ®Google Scholar
• Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009;45:574–578. doi:10.1016/j.oraloncology.2008.07.010
   PubMed Web of Science ®Google Scholar
• Dillon PM, Petroni GR, Horton BJ, et al. A Phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2017;23:4138–4145. doi:10.1158/1078-0432.CCR-16-2942
   PubMed Web of Science ®Google Scholar
• Keam B, Kim SB, Shin SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015;121:2612–2617. doi:10.1002/cncr.29401
   PubMed Web of Science ®Google Scholar
• Kim DW, Oh DY, Shin SH, et al. A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer. 2014;14:795. doi:10.1186/1471-2407-14-795
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005;23:585–590. doi:10.1200/JCO.2005.06.125
   PubMed Web of Science ®Google Scholar
• Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck. 2005;27:1022–1027. doi:10.1002/hed.20274
   PubMed Web of Science ®Google Scholar
• Ochel HJ, Gademann G, Röcken C, Wördehoff H. Effects of imatinib mesylate on adenoid cystic carcinomas. Anticancer Res. 2005;25:3659–3664.
   PubMed Web of Science ®Google Scholar
• Agulnik M, Cohen EWE, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007;25:3978–3984. doi:10.1200/JCO.2007.11.8612
   PubMed Web of Science ®Google Scholar
• Ganesan P, Piha-Paul S, Naing A, et al. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014;32:279–286. doi:10.1007/s10637-013-9966-3
   PubMed Web of Science ®Google Scholar
• Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol. 2012;23:1562–1570. doi:10.1093/annonc/mdr522
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Parise RA, Ramananthan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007;13:3605–3610. doi:10.1158/1078-0432.CCR-07-0162
   PubMed Web of Science ®Google Scholar
• Goncalves PH, Heilbrun LK, Barrett MT, et al. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget. 2017;8:32918–32929. doi:10.18632/oncotarget.16464
   PubMedGoogle Scholar
• Even C, Lassen U, Merchan J, et al. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Invest New Drugs. 2020;38:402–409. doi:10.1007/s10637-019-00739-x
   PubMed Web of Science ®Google Scholar
• Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II study of lenvatinib in patients with progressive recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37:1529–1537. doi:10.1200/JCO.18.01859
   PubMed Web of Science ®Google Scholar
• Locati LD, Galbiati D, Calareso G, et al. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life. Cancer. 2020;126:1888–1894. doi:10.1002/cncr.32754
   PubMed Web of Science ®Google Scholar
• Atallah S, Casiraghi O, Fakhry N, et al. A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors. European Journal of Cancer. 2020;130:241–249. doi:10.1016/j.ejca.2020.01.023
   PubMed Web of Science ®Google Scholar
• Fendler WP, Reinhardt S, Ilhan H, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8:3581–3590. doi:10.18632/oncotarget.12240
   PubMedGoogle Scholar
• Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology. 2009;62(10):e1–e34. doi:10.1016/j.jclinepi.2009.06.006
   PubMed Web of Science ®Google Scholar